Anti-PD-1 based ICB is now a first- or second-line treatment, alone or in combination for a number of cancers including non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC), however, many patients still do not respond to ICB, and some cancers are largely resistant. The gene discussed is PDCD1; the disease is renal cell carcinoma.